266,334 Shares in Inogen, Inc $INGN Purchased by Readystate Asset Management LP

Readystate Asset Management LP acquired a new stake in shares of Inogen, Inc (NASDAQ:INGN) during the 2nd quarter, Holdings Channel.com reports. The fund acquired 266,334 shares of the medical technology company’s stock, valued at approximately $1,718,000.

Several other hedge funds also recently made changes to their positions in INGN. Quarry LP acquired a new stake in shares of Inogen during the 4th quarter valued at approximately $27,000. Prelude Capital Management LLC bought a new stake in Inogen during the third quarter valued at $82,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Inogen in the 3rd quarter worth about $90,000. Integrated Wealth Concepts LLC bought a new position in shares of Inogen in the 1st quarter worth about $85,000. Finally, Corient Private Wealth LLC acquired a new position in shares of Inogen in the 4th quarter valued at about $84,000. Institutional investors and hedge funds own 89.94% of the company’s stock.

Insider Buying and Selling

In other Inogen news, EVP Jennifer Yi Boyer sold 10,938 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $6.60, for a total value of $72,190.80. Following the completion of the transaction, the executive vice president owned 5,039 shares in the company, valued at approximately $33,257.40. This represents a 68.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 2.50% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inogen in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Inogen has a consensus rating of “Moderate Buy”.

Inogen Stock Performance

INGN stock opened at $5.42 on Tuesday. The stock has a market capitalization of $143.85 million, a price-to-earnings ratio of -6.02 and a beta of 1.57. Inogen, Inc has a 1 year low of $5.29 and a 1 year high of $9.13. The stock’s fifty day moving average is $6.11 and its two-hundred day moving average is $6.34.

Inogen (NASDAQ:INGN) last released its quarterly earnings results on Thursday, August 6th. The medical technology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.01. Inogen had a negative net margin of 6.94% and a negative return on equity of 13.17%. The business had revenue of $95.08 million during the quarter, compared to analyst estimates of $95.23 million.

Inogen Profile

Inogen, Inc (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen.